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ABSTRACT
Background Splanchnic vasodilation triggers the
development of the hyperdynamic circulatory syndrome
in portal hypertension. Neuropeptide Y (NPY),
a sympathetic co-transmitter of norepinephrine,
improves contractility in mesenteric arteries of
pre-hepatic portal hypertensive rats. Therefore, we
investigated the effect of NPY on mesenteric arterial
contractility in vitro and in vivo in cirrhotic ascitic rats, as
well as the vasoactive pathways involved.
Methods All experiments were performed in
CCl4-induced cirrhotic rats with ascites and compared to
controls. In vivo haemodynamic characterisation was
assessed before and after cumulative application of NPY
i.v. using the microspheres technique. In vitro mesenteric
arterial perfusion was used to analyse the effect of NPY
on the response to a1-adrenergic, as well as nitrergic
stimulation. The NPY effects on vasoactive pathways
(RhoA/Rho-kinase and NOS/NO) were analysed by
western blot in mesenteric arteries.
Results NPY decreased portal-venous blood flow and
reduced portal pressure in cirrhotic rats, without changes
in mean arterial pressure. This was accompanied by
decreased cardiac output and normalised systemic
vascular resistance in cirrhotic rats. By contrast, no
significant splanchnic or systemic haemodynamic effect
of NPY was seen in controls. NPY enhanced arterial
contractility in cirrhotic but not in control rats.
Furthermore, NO-mediated vasodilation was reduced to
a greater extent than in controls. These findings were
paralleled by an increased expression and activity of the
constrictive Rho-kinase pathway and decreased
activation of vasodilating NOS/NO signalling after NPY
administration in mesenteric arteries.
Conclusions NPY exerts marked portal hypotensive
effects and ameliorates the hyperdynamic circulation in
cirrhotic ascitic rats. This is mediated mainly by
a pronounced splanchnic vasoconstriction and reduction
in splanchnic blood flow due to enhanced Rho-kinase
expression and activity, as well as reduced NOS
activation and NO effect.
INTRODUCTION
Splanchnic arterial vasodilation is the pathophysi-
ological hallmark in the development of the
hyperdynamic circulatory syndrome and the asso-
ciated haemodynamic derangements in portal
hypertension.1 This is due to (1) marked vascular
overproduction of vasodilators, mainly nitric oxide
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Significance of this study
What is already known on the subject?
< Portal hypertension and the hyperdynamic
circulatory syndrome (HCS) are the cause of
most complications limiting prognosis in
advanced cirrhosis.
< Splanchnic vasodilation is the pathophysiolog-
ical hallmark for the development of the HCS,
aggravates portal hypertension and has been
attributed mainly to vascular NO production and
defective RhoA-/Rho kinase signalling in the
mesenteric circulation.
< Advanced cirrhosis associates with a marked
stimulation of the sympathetic nervous system
aiming to counterbalance arterial vasodilation.
< Neuropeptide Y (NPY) is a sympathetic neuro-
transmitter known to facilitate a-adrenergic
vasoconstriction. In mesenteric arteries this
vasoaction is more pronounced in pre-hepatic
portal hypertensive rats and, thus, corrects
vascular hyporeactivity.
What are the new findings?
< NPY is the first vasoactive substance exerting
(in vitro and in vivo) higher vasoconstrictive
action in the splanchnic circulation in portal
hypertension than in healthy conditions making
this peptide a superior candidate to counterbal-
ance splanchnic vasodilation.
< Acute administration of NPY i.v. in vivo reduces
portal hypertension by more than 20% and
markedly attenuates the hyperdynamic circula-
tion in decompensated cirrhotic rats.
< This most beneficial haemodynamic effect of
NPY is due to its dual effect namely, inhibition of
vascular NO overproduction as well as restora-
tion of defective RhoA/Rho-kinase signalling
in the mesenteric circulation during portal
hypertension.
How might it impact on clinical practice in the
foreseeable future?
< NPY should be tested for its haemodynamic
effects in cirrhotic patients potentially leading to
a new therapeutic agent increasing the phar-
macological armentarium available for treatment
of portal hypertension.
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(NO); and (2) vascular hyporeactivity to endogenous vasocon-
strictors.2 Many studies report enhanced extrahepatic expression
of NO synthases (inducible, endothelial and neuronal) associated
with a marked vascular NO overproduction contributing to
splanchnic vasodilation.2e7 Moreover, splanchnic vascular hypo-
contractility to vasoconstrictors is at least partially due to defec-
tive intracellular contractile signalling.8e10 In humans and
animals with cirrhosis, this splanchnic hypocontractility is
accompanied by a downregulated and defective RhoA/Rho-kinase
pathway, which is crucial for maintaining vascular tone.10e12
This splanchnic vasodilation sustains underﬁlling of the effective
central blood volume and activation of vasoconstrictors. There-
fore, improvement of splanchnic vasoconstriction is an important
goal in therapy of portal hypertension and liver cirrhosis.
Stimulation of the sympathetic nervous system (SNS) might
counterbalance this arterial vasodilation in portal hyperten-
sion.13 Neuropeptide Y (NPY) is co-stored and co-released with
norepinephrine from secretory vesicles of sympathetic nerve
terminals.14 NPY, predominantly located in sympathetic nerves
of small arterioles is one regulator of vascular resistance.15 It
potently facilitates adrenergic vasoconstriction by sensitising
vascular smooth muscle for norepinephrine, even though the
exact mechanism is unknown.16e18 We have reported previously
that NPY augments maximal a1-adrenergic vasoconstriction and
thereby, corrects vascular hyporeactivity in a pre-hepatic model
of portal hypertension.19 20 The potentiative vasoconstrictive
capacity of NPY was more pronounced in mesenteric arteries of
portal hypertensive rats as compared to control rats. This indi-
cates an important NPY-induced compensatory mechanism
counterbalancing arterial vasodilatation and restoring the efﬁ-
cacy of endogenous catecholamines in the splanchnic circulation
in portal hypertension. However, the haemodynamic effects of
NPY in cirrhotic portal hypertension and the involved mecha-
nisms remain unexplored. Therefore, we studied the effects of
exogenous NPY in vivo as well as in vitro in the mesenteric
circulation in cirrhotic rats with portal hypertension as well as
involved molecular mechanisms.
MATERIAL AND METHODS
Animals
The investigation was performed in male SpragueeDawley rats
(Harlan Sprague Dawley Laboratories, Indianapolis, Indiana,
USA), weighing 300e399 g. Rats were caged at a constant room
temperature of 218C, exposed to a 12:12 h light:dark cycle, and
allowed free access to water and standard rat chow.
CCl4-induced liver cirrhosis
Cirrhosis was induced in male pathogen-free CD rats (Charles
River, 50e80 g initial weight) by inhalation of CCl4 along with
phenobarbital (0.35 g/l) in the drinking water, as previously
described.21 22 The CCl4 administration was started three times
a week over 1 min and increased every other week by 1 min to
a maximum of 5 min, depending on change in body weight.
After 12 to 16 weeks, this approach induces micronodular liver
cirrhosis with ascites. Seven days prior to experimental proce-
dures application of CCl4 as well as phenobarbital was stopped.
Only cirrhotic animals with decompensation of liver function
and thus presence of ascites were used. Phenobarbital-treated
age- and sex-matched rats were used as control group.
In vivo haemodynamic studies
Median laparotomy was performed, and a PE-50 catheter was
introduced into a small ileocaecal vein and advanced to the
portal vein for the measurement of portal pressure (PP) as
previously described.12 The left femoral artery was cannulated
with PE-50 catheters for measurement of mean arterial pressure
(MAP). Via the right carotid artery, another PE-50 catheter was
advanced into the left ventricle under pulse curve control. This
catheter was used for microsphere application. The catheters in
the femoral artery and the portal vein were connected to
a pressure transducer (Statham, Oxnard, California, USA) and
continuously recorded (Powerlab Quadbridge and Powerlab 4/20;
AD Instruments, Spechbach, Germany). The zero point was
1 cm above the operating table. After insertion of all catheters,
rats were allowed to stabilise haemodynamically for 30 min.
NPY was administrated intravenously as bolus (0.1 ml) in
a cumulative manner in doses ranging from 0.005 nmol up to
100 nmol and MAP and PP were monitored continuously for
a further 20 min, followed by application of the microsphere
technique.
Microsphere technique
Cardiac output was measured using the coloured microsphere
method as previously described.12 23 The coloured microsphere
technique was validated by the more frequently used radioactive
microsphere method. It has the advantage of being non-radio-
active. A reference sample was obtained for 1 min at a rate of
0.65 ml/min, using a continuous withdrawal pump (Hugo Sachs
Elektronik, March-Hugstetten, Germany). About 300 000 yellow
microspheres (15 mm diameter; Triton Technologies, San Diego,
California, USA) were suspended in 0.3 ml saline containing
0.05% Tween and injected in the left ventricle 10 s after the
withdrawal pump had been started. Mesenteric portal-systemic
shunt volume was estimated after injection of 150 000 blue
microspheres in 0.3 ml saline containing 0.05% Tween in an
ileocaecal vein within 30 s.
The blood reference probe was digested by addition of 3.8 ml
5.3 M KOH and 0.5 ml Tween 80 and subsequent boiling for 1 h.
The digested tissues and blood samples were vortexed and ﬁltered
using Whatman Nucleopore ﬁlters (Whatman International,
Maidstone, UK). The colour of the ﬁltered microspheres was
dissolved in 0.2 ml dimethyl formamide, and the absorption was
measured using spectrophotometry. Thereafter, cardiac output
and organ blood ﬂow was calculated using software obtained
from Triton Technologies and expressed per 100 g body weight.
Splanchnic perfusion pressure was deﬁned as MAP minus PP.
Splanchnic vascular resistance was calculated from the ratio
between splanchnic perfusion pressure and the measured
splanchnic blood ﬂow, without including hepatic arterial ﬂow.
Mesenteric portal-systemic shuntﬂow was measured as the
fraction of blue micropheres in the lung from total blue micro-
spheres injected in an ileocaecal vein. Hepatic portal-vascular
resistance was estimated as PP divided by the sum of gastroin-
testinal and splenic perfusion minus mesenteric portal-systemic
shuntﬂow. Systemic vascular resistance (SVR) was calculated as
the ratio between MAP and cardiac output. Vascular resistance of
speciﬁc organs (kidney, spleen, liver, stomachegut) was calcu-
lated as the ratio between MAP and organ blood ﬂow (table 1).
In vitro perfusion
The in vitro perfusion system used was a partial modiﬁcation of
that originally described by McGregor and used extensively in
previous studies in our laboratory.24 25 Brieﬂy, the superior
mesenteric artery (SMA) was cannulated with a PE-60 catheter
and gently perfused with 15 ml warm Krebs solution to elimi-
nate blood. After isolating the SMA with its mesentery, the gut
was cut off close to its mesenteric border. The arterial vascula-
ture was then transferred to a 378C water-jacketed container and
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perfused with oxygenated 378C Krebs solution (95% O2, 5%
CO2) using a roller pump (Isamtec, IPC 8-channel; Glattburg,
Zürich, Switzerland). The Krebs solution had the following
composition (in mmol/l): NaCl, 118; KCl, 4.7; KH2PO4, 1.2;
MgSO4, 1.2; CaCl2, 2.5; NaHCO3, 25; disodium EDTA, 0.026;
and glucose, 11.0; pH 7.4. The efﬂuent of the perfused tissue was
continuously removed from the perfusing chamber. The perfu-
sion pressure was measured with a P-23-Db strain gauge trans-
ducer (Statham) on a side arm just before the perfusing cannula
and continuously recorded (Powerlab Quadbridge and Powerlab
4/20; AD Instruments).
Where indicated, endothelial denudation of the mesenteric
vasculature was performed by a combined treatment of cholic
acid (sodium salt) and distilled water as has been used before.26 In
brief, after cannulation of the SMA and gentle ﬂushing with
10 ml of warmed Krebs solution to eliminate blood, perfusion
with cholic acid (0.5%/1.5 ml for 10 s) followed by 15 ml of Krebs
solution (to eliminate cholic acid) was performed. The prepara-
tion was then transferred to the 378C water-jacketed container
and perfused with oxygenated 378C Krebs solution (4 ml/min)
for 10 min. After the mesenteric vasculature was relaxed, 378C
warmed distilled water was perfused for 10 min before starting
Krebs perfusion again. After an equilibration period of 45 min,
experimental perfusion protocols were performed (ﬁgure 1). At
the end of each experiment we assessed whether the vessel was
completely de-endothelialised and whether the smooth muscle
function was maintained. The mesenteric preparation was
kept preconstricted with methoxamine (MT; alpha-1-agonist:
100 mM) and dose-dependent vasorelaxation to the endothelium-
dependent vasodilator acetylcholine (ACh: 108 to 106 g, bolus
of 0.1 ml) and the endothelium-independent vasodilator sodium
nitroprusside (SNP: 106 to 105 g, bolus of 0.1 ml) was tested.
Only experiments with ACh-/ and SNP-induced relaxation being
less/more than 15%/60% were accounted as valid.
In vitro study protocol
Baseline perfusion at 4 ml/min was established for 30 min before
different study protocols were performed. Where indicated, two
perfusion cycles following the same pharmacological test were
done. After completion of the ﬁrst perfusion cycle and a wash-
out period of 45 min, NPY (50 nM) was added and a second
perfusion cycle was initiated after 10 min of incubation time. It
is important to stress that in preliminary studies, 50 nM NPY
concentration was found to have no intrinsic direct vasocon-
strictive action and did not potentiate vasoconstriction at low
and medium vascular tone. NPY was present at the same molar
concentration in the perfusion system throughout the second
perfusion cycle. As shown previously the perfusion system
showed stable basal perfusion conditions and unchanged pressor
responsiveness for the time period necessary for this experi-
mental protocol.
Protocol I: NPY-evoked vasoconstriction in vitro
This protocol was performed in de-endothelialised mesenteric
preparations. Considering the well-known enhanced release of
endothelium-derived vasodilators mainly nitric oxide, in portal
Table 1 In vivo haemodynamic data before and after administration of neuropeptide Y (NPY)
Parameter
Control Cirrhosis
Basal NPY Basal NPY
Mean arterial pressure (mmHg) 120.165 118.869 101.467* 99.969*
HR (/min) 227.5622.7 257630 362.7625.3** 323636** yy
Portal pressure (mmHg) 7.560.6 7.760.5 14.160.8*** 10.960.5* yyy
CO (ml/min/100 g) 18.662.3 18.962.3 30.564.6* 23.763.8** yy
Systemic vascular resistance (mmHg/min/100 g/ml) 6.460.5 6.260.5 4.260.6* 6.361.5y
SpBF (ml/min/100 g) 1.960.5 1.860.4 5.660.8** 4.060.5** y
Splanchnic vascular resistance (mmHg/min/100 g/ml) 62.1610.9 72.7618 18.864.1** 26.669** y
HABF (ml/min/100 g) 2.260.2 1.860.4 3.560.6* 2.860.5
HPVR (mmHg/min/100 g/ml) 1.860.2 2.260.4 2.360.4 1.560.2
Renal blood flow (ml/min/100 g) 1.3660.38 0.9160.36y 1.8960.69 1.8560.70*
Renal vascular resistance (mmHg/min/100 g/ml) 0.0660.02 0.0660.01 0.0760.02 0.0960.07
Mes-portal shuntz (ml/min/100 g) d d 0.4561.1 0.3960.4
zObtained in a separate set of experiments versus basal: *p<0.05; **p<0.01; ***p<0.001/versus basal: yp<0.05; yyp<0.01;
yyyp<0.001.
CO, cardiac output; HABF, hepatic arterial blood flow; HPVR, hepatic portal vascular resistence; HR, heart rate; SpBF, Splanchnic blood flow.
Figure 1 Effect of neuropeptide Y
(NPY) on portal pressure (A) and mean
arterial pressure (B) in control (n¼7)
and cirrhotic ascitic rats (LC, n¼8).
*: p<0.05 versus basal; o: p<0.05
versus control rats. LC, liver cirrhosis;
PP, portal pressure.
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hypertension in the splanchnic circulation by this approach we
avoided potential differences in shear-mediated release of endo-
thelium-derived vasodilators, between the study groups. In order
to test a direct vasoconstrictive effect, NPY was administered as
repeated boluses (0.1 ml) at increasing doses (0.1 nM to 10 mM) in
intervals of 2e4 min in the absence of vasoconstrictors (at base-
line conditions). In a different protocol, mesenteric tissue prepa-
rations were preconstricted with MTand after reaching a stable
preconstriction plateau, cumulative doseeresponse curves to
NPY, administered in the form of repeated boluses at increasing
doses (see above) were obtained. In order to test for the differ-
ences in NPY-induced vasoconstriction dependent on the degree
of a1-adrenergic stimulation increasing levels of a1-adrenergic
preconstriction using 0.3, 1, 3 and 10 mM of MTwere applied.
Protocol II: NPY-induced facilitation of a1-adrenergic
vasoconstriction in vitro
This protocol was performed in intact mesenteric preparations.
Non-cumulative dose-response curves for MT (0.3e300 mM)
were performed by continuous infusion for 2 min for each dose
administered (ﬁrst and second perfusion cycle).
Protocol III: NPY effect on eNOS-dependent vasorelaxation in
vitro
Intact mesenteric vessel preparations were pre-constricted with
MT (EC80). After achieving a stable pre-constriction level, the
preparation was stimulated by increasing doses of ACh (108 to
105 M). AChwas given in non-cumulative manner administered
as repeated boli (0.1 ml) in the ﬁrst and second perfusion cycle.
Protocol IV: NPY effect on nitrergic vasorelaxation in vitro
Periarterial nerve stimulation (PNS) was used to investigate non-
adrenergic and non-cholinergic vasorelaxation in de-endothe-
lialised mesenteric arteries. Two platinum electrodes, one placed
around the SMA and the other shaped as a wire grid the tissue
was resting on, were used for transmural electrical ﬁeld stimu-
lation. The nerves of the preparation were stimulated by means
of an electronic stimulator (I-ZQ4v; Hugo Sachs Electronics,
Hugstetten, Germany), delivering single square-wave pulses
(2 ms) at 45 V with a train duration of 30 s and frequencies of
2e12 Hz. In order to evaluate vasodilatory responsiveness
vessels were preconstricted submaximally (EC80) using norepi-
nephrine (NE 105 M) before applying PNS. nNOS-mediated
vasorelaxation is known to be non-adrenergic and non-cholin-
ergic in origin. Therefore, guanethidine (53105 M), atropin
(109 M) and timolol (109 M) were added from the beginning
in order to deplete endogenous norepinephrine stores and to
prevent its uptake as well as to avoid cholinergic stimulation.
When a stable preconstriction level was achieved, PNS was
applied in a non-cumulative fashion. Sufﬁcient time was allowed
between each stimulation train for the perfusion pressure to
return to a stable level, usually within 5e10 min. PNS responses
are expressed as percentage change of the pre-constriction level
present before PNS. Nitrergic vasodilation is known to be
independent of prostaglandin synthesis27 and it is not subject of
pre-junctional inhibition by a2-adrenoreceptors.27
Western blotting
In ﬁve control as well as ﬁve cirrhotic CCl4 rats, 50 nM NPY was
administrated through the femoral vein. After 1 h, animals were
sacriﬁced for tissue harvesting to study the RhoA/Rho-kinase
and nitric oxide synthase/protein kinase G (NOS/PKG) activity.
Respectively, control and cirrhotic CCl4 rats after administration
of vehicle in the femoral vein served as controls. Samples of
shock-frozen mesenteric arteries were homogenised in a buffer
containing 25 mM Tris/HCl, 5 mM ethylenediamine tetraacetic
acid, 10 mM phenylmethanesulfonyl ﬂuoride, 1 mM benzami-
dine, and 10 mg/ml leupeptin.12 28 Samples were diluted with
sample buffer. Protein determination of the homogenates was
performed with the Dc-Assay kit (Biorad, Munich, Germany).
Samples (20 mg of protein/lane) were subjected to SDS-PAGE
(15% gels for RhoA; 8% gels for Rho-kinase, iNOS, eNOS and
p-eNOS; 10% gels for moesin, p-moesin, VASP and p-VASP), and
proteins were blotted on nitrocellulose membranes. The
Figure 2 Portal tributary flow (A),
splanchnic vascular resistance (B),
cardiac output (C) and systemic
vascular resistance (D) in control (n¼7)
and cirrhotic ascitic rats (LC, n¼8) after
acute intravenous administration of
neuropeptide Y (NPY). *: p<0.05
versus LC, o: p<0.05 and oo: p<0.01
versus control. LC, liver cirrhosis.
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membranes were blocked, incubated with primary antibodies:
RhoA 119, Rock-2 H-85, NOS3, moesin, p-moesin, VASP and
GAPDH from Santa Cruz Biotechnology (Santa Cruz, California,
USA); iNOS (ab49999) from Abcam (Cambridge, UK); p-eNOS
(Ser 1177) from Cell Signaling (Boston, Massachusetts, USA); p-
VASP clone 16C2 from Calbiochem (San Diego, California, USA).
Thereafter the membranes were incubated with the corre-
sponding secondary peroxidase-coupled antibodies (Calbiochem).
Blots were developed with enhanced chemiluminescence (ECL,
Amersham, UK). Intensities of the resulting bands on each blot
were compared densitometrically with a FLA-3000 phosphoim-
ager (Fuji-Film, Düsseldorf, Germany).
Assessment of PKG and Rho kinase activity
PKG activity was assessed as phosphorylation of the endogenous
PKG substrate, VASP, at Ser-239. The phosphorylation state of
VASP serves as a marker for PKG activity. Rho-kinase activity
was assessed as phosphorylation of the endogenous Rho kinase
substrate, moesin, at thr-558. This was done by western blot
analysis using site- and phosphospeciﬁc antibodies.12 28
Statistical analysis
Results were expressed as mean6SE. Statistical analysis was
performed using ANOVA (two-way, with repeated measure-
ments) or the paired and unpaired Student t test if appropriate.
The statistical signiﬁcance level was p<0.05.
RESULTS
Animals
There were no signiﬁcant differences in body weight in the
experimental groups (446623 g for cirrhotic and 380615 g
for control rats, respectively). Cirrhotic rats showed elevated
spleen weights, expressed as percentage of body weight
(3.9060.24 g/kg b.w. vs sham: 2.4460.23 g/kg b.w., p<0.0001).
In vivo haemodynamic studies
As expected, cirrhotic rats presented with markedly increased PP
when compared to control rats (ﬁgure 1A). Intravenous NPY
application caused a dose-dependent decrease in PP in cirrhotic
rats without signiﬁcantly altering PP in control rats (ﬁgure 1A).
Basal MAP was signiﬁcantly lower in cirrhotic rats as compared
to control rats (ﬁgure 1B). NPY had no signiﬁcant effect on MAP
at any dose given in both groups. Cirrhotic rats exhibited
a marked hyperdynamic circulation with signiﬁcantly enhanced
cardiac output and portal tributary blood ﬂow associated with
a markedly decreased systemic and splanchnic vascular resistance
(ﬁgure 2). Intravenous application of NPY elicited a signiﬁcant
drop in portal tributary blood ﬂow (ﬁgure 2A) and cardiac output
(ﬁgure 2C) in conjunction with a marked increase in splanchnic
Figure 3 Change in portal tributary
flow (A), splanchnic vascular resistance
(B), cardiac output (C) and systemic
vascular resistance (D) induced by
neuropeptide Y (NPY) in control (n¼7)
and cirrhotic ascitic rats (LC, n¼8).
o: p<0.05 versus control. LC, liver
cirrhosis.
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Figure 4 Neuropeptide Y (NPY)-evoked potentiation of a1-adrenergic
vasoconstriction in dependency on the level of sympathoadrenergic
activity. Doseeresponse curves of NPY in mesenteric vasculature after
removal of the endothelium and pre-constricted with different doses of
methoxamine: A: low (1 mM) and medium dose (3 mM) and B: high dose
(10 mM) of MT used for pre-constriction. Measurements represent at
least three experiments for each study group and dose of MT used.
*p<0.05 versus control. MT, methoxamine.
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and systemic vascular resistance in cirrhotic rats (ﬁgure 2B,D),
without hepatic or renal effects (table 1). In contrast, in control
rats, NPYonly caused a slight but not signiﬁcant amelioration in
portal tributary blood ﬂow and no change in cardiac output and
systemic haemodynamics (ﬁgure 3). NPY did abrogate the basal
difference in cardiac output and systemic vascular resistance
between the study groups (ﬁgure 3). Changes in portal tributary
blood ﬂow, cardiac output and systemic vascular resistance
induced by NPY were signiﬁcantly greater in cirrhotic rats as
compared to control rats (ﬁgure 3). This strongly indicates
a more pronounced vasoaction of NPY in the splanchnic circu-
lation in cirrhotic rats as compared to control rats (ﬁgure 1e3).
In vitro perfusion experiments
Baseline perfusion pressures for all study protocols were signiﬁ-
cantly lower in cirrhotic rats as compared to sham rats evidencing
the presence of arterial vasodilation (7.261 mm Hg vs
11.460.7 mm Hg, p<0.0001). Removal of the endothelium
signiﬁcantly increased baseline pressures in both groups, rendering
baseline conditions no more signiﬁcantly different between
cirrhotic and control rats (14.461.8 mm Hg vs 16.561.1 mm Hg).
NPY-evoked vasoconstriction in vitro in de-endothelialised
mesenteric arteries
As reported earlier NPY did not induce any signiﬁcant effect in
the absence of vasoconstrictors demonstrating a clear lack of
direct vasoconstrictive action (data not shown). However, after
MT-induced preconstriction NPY enhanced a1-adrenergic vaso-
constriction in a dose-dependent manner (ﬁgure 4). Since
experiments were performed in de-endothelialised mesenteric
preparations this effect conﬁrms the endothelium-independent
mode of action of NPY on vascular smooth muscle. The various
pre-constriction levels in mesenteric preparations used were not
signiﬁcantly different between groups (data not shown). The
Figure 5 Vascular responsiveness to a1-
adrenergic stimulation in mesenteric arteries in
cirrhotic ascitic and sham rats before and after
neuropeptide Y (NPY) incubation. A marked
vascular hyporesponsiveness to methoxamine
can be appreciated between LC (n¼6) and
control animals (n¼6) in the absence of NPY
(A). After incubation with NPY vascular
sensitivity and maximal contractility were no
longer different between study groups (B).
Changes in pressure response to methoxamine
induced by NPY presented as absolute change
in perfusion pressures as compared to values
obtained during the first perfusion cycle (C).
Changes in pressure response presented as
percentage of perfusion pressure obtained
during first perfusion cycle (D). n¼6 for LC and
control animals. *p<0.01; **p<0.001 versus
sham animals. LC, liver cirrhosis.
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effect of NPY on a1-adrenergic vasoconstriction did increase in
magnitude with increasing levels of a1-adrenergic pre-constric-
tion. For instance, NPY-induced increases in perfusion pressure
were signiﬁcantly greater when administered to vessels
pre-constricted at 3 mM as compared to 1 mM and the latter
effect being greater than the one observed at 0.3 mM (ﬁgure 4A;
p<0.001 by ANOVA, respectively). At low and medium
a1-adrenergic pre-constriction (MT: 0.3; 1 and 3 mM, respec-
tively) cumulative doseeresponse curves for NPY were not
signiﬁcantly different between cirrhotic and control rats
(ﬁgure 4A). In contrast, after adrenergic preconstriction using
high doses of MT (10 mM) NPY-evoked vasoconstriction of
de-endothelised arterial mesenteric bed was signiﬁcantly more
marked in cirrhotic than in control animals (ﬁgure 4B).
Effect of NPY on a1-adrenergic vasoconstriction in vitro in
mesenteric arteries with intact endothelium
Cirrhotic ascitic rats presented the well-known vascular hypo-
reactivity of intact mesenteric arteries to a1-adrenergic stimu-
lation by MT (ﬁgure 5A). It is important to note that vascular
sensitivity was not markedly decreased in cirrhotic rats whereas
vascular contractility was markedly decreased (ﬁgure 5). After
incubation with NPY, and in the presence of NPY, the vascular
response to MT was no longer signiﬁcantly different between
the study groups (ﬁgure 5B). The change in vascular sensitivity,
namely a left-ward shift of the MT doseeresponse curve, was
similar in cirrhotic and healthy control rats (EC50: 9.561.7 vs
20.761.9 mM and 14.162.0 vs 27.364.7 mM, respectively).
However, the efﬁcacy of MTat Emax was markedly augmented in
cirrhotic rats but was not signiﬁcantly altered in sham animals.
Therefore, the NPYeffect on vascular contractility was markedly
more pronounced in cirrhotic rats. In fact, the improvement
in pressure response induced by NPY at high concentrations of
MT (>10 mmol/l) expressed as absolute changes in perfusion
pressure was signiﬁcantly higher in cirrhotic animals than in
control rats (ﬁgure 5C). Expressing data as per cent change from
the response obtained in the ﬁrst perfusion cycle (in the absence
of NPY) induced by NPY cirrhotic rats responded signiﬁcantly
more than control rats at high (>10 mmol/l) but not at low doses
of the a1-adrenergic agonist (ﬁgure 5D).
NPY-induced inhibition of vasorelaxation
PNS induced vasorelaxation in de-endothelialised mesenteric
arteries. (ﬁgure 6). Vasodilator response to acetylcholine at the
highest dose used was 9.565% and 9.066% in cirrhotic and
control rats, respectively (NS) demonstrating a sufﬁcient de-
endothelialisation. Vasodilator response to sodium nitroprusside
at the highest used dose was 7567% and 7869% for cirrhotic
and control rats (NS) demonstrating the functional integrity of
the vascular smooth muscle in the vascular bed studied.
NE-induced pre-constriction levels were similar in both study
groups (8666 vs 9165 mm Hg) indicating similar vascular tone
before neuronal stimulation. Incubation with NPY did not affect
baseline or pre-constriction levels in either group. All vessels
responded to PNS with a frequency-dependent decrease in
perfusion pressure (ﬁgure 6A). This neurally mediated
Figure 6 Effect of neuropeptide Y
(NPY) on nitrergic vasodilation in
de-endothelialised mesenteric arteries,
as well as its effect on eNOS-
dependent vasodilation in mesenteric
arteries with intact endothelium of
cirrhotic ascitic and sham rats.
Absolute pressure decrease induced by
perivascular electrical nerve stimulation
before (A) and after (B) NPY incubation.
After NPY addition no more significant
differences in frequency-dependent
neural vasorelaxation was observed
between study groups. Changes in
nitrergic vasodilation induced by NPY
(C) reveal a more pronounced inhibitory
action of NPY in cirrhotic rats (LC
group: n¼6, sham group: n¼6).
Absolute pressure decrease induced by
acetylcholine before (D) and after (E)
NPY incubation. After NPY addition no
more significant differences in eNOS-
dependent vasorelaxation was
observed between study groups.
Changes in eNOS-dependent
vasodilation induced by NPY (F) reveal
a more pronounced inhibitory action of
NPY in cirrhotic rats (LC group: n¼4,
sham group: n¼4). eNOS, endothelial
nitric oxide synthase; LC, liver cirrhosis.
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vasodilatory response was signiﬁcantly more pronounced in
cirrhotic as compared to sham rats (ﬁgure 6A). NPY abolished
this difference in PNS-induced vasorelaxation between the study
groups (ﬁgure 6B). When expressing PNS-induced vasorelaxation
as per cent change from pre-constriction level a markedly
increased response was observed in vessel preparation from
cirrhotic rats as compared to control rats (ﬁgure 6C).
Acetylcholine-induced vasorelaxation represents eNOS-
dependent vasodilation and was enhanced in cirrhotic ascitic rats
as compared to control rats (ﬁgure 6D). NPY inhibited eNOS-
dependent vasorelaxation and thereby, abolished the difference
between both study groups (ﬁgure 6E). In fact, the per cent
change of vasorelaxation induced by NPY was more pronounced
in cirrhotic rats as compared to control animals (ﬁgure 6F).
Effect of NPY on expression and activity of vasoactive proteins
in mesenteric arteries of control rats
NPY administration elicited no signiﬁcant changes in mesenteric
expression of RhoA and total moesin in controls (data not
shown), while an important increase in expression of Rho-kinase
was observed (ﬁgure 7A). The activity of Rho-kinase was three
times elevated by NPY, as measured by phosphorylation of its
substrate moesin (ﬁgure 7A).
This activation of the contracting signalling RhoA/Rho-kinase
was parallelled by a reduced NO effect at the same extent. This
was analysed as a 60% drop in activity of the NO effector
PKG, measured as the phosphorylation of its substrate VASP
(ﬁgure 7B). This was due to inhibition of eNOS activation,
measured as its phosphorylation, as well as decreased expression
of iNOS (ﬁgure 7B).
Effect of NPY on expression and activity of vasoactive
proteins in mesenteric arteries of cirrhotic rats
Similarly to controls NPY administration elicited no signiﬁcant
changes in mesenteric expression of RhoA and total moesin in
cirrhotics, while an important increase in expression of
Rho-kinase was observed (ﬁgure 8A). The activity of Rho-kinase
in cirrhotic mesenteric arteries was elevated by NPY by a factor
of 7, as measured by phosphorylation of its substrate moesin
(ﬁgure 8A).
The enhanced activation of eNOS and expression of iNOS
were decreased by approximately 30% as shown in ﬁgure 8B.
NPY administration decreased through this the NO effect by
50%, analysed as the PKG activity phosphorylating its substrate
VASP (ﬁgure 8B).
DISCUSSION
Vascular dysfunction in the splanchnic circulation during portal
hypertension is characterised by vascular hyporeactivity to
adrenergic stimulation and enhanced NO-mediated
Figure 7 Vasomotoric protein expression and activity in superior mesenteric artery in control rats without neuropeptide Y (NPY) (n¼5) and after i.v.
NPY administration (n¼5). Mesenteric expressions of vasoconstrictive pathway proteins RhoA, Rho-kinase and moesin were determined by western
blot analysis (A). Mesenteric expressions of vasodilating proteins eNOS, iNOS and VASP were analysed using western blot (B). Phosphorylation of
moesin, eNOS, VASP, and endogenous control GAPDH were determined by western blot analysis using phospho- and site-specific antibodies. Shown
are relative densitometric quantifications (means6SEM) of all experiments with values of controls set to 100 d.u. and representative western blots
(minimum was n¼5/group). d.u., density unit; eNOS, endothelial nitric oxide synthase; iNOS, inducible nitric oxide synthase; LC, liver cirrhosis; PKG,
protein kinase G; VASP, vasodilator-stimulated phosphoprotein.
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vasorelaxation leading to arterial vasodilation. Here, we report
that NPY counteracts both of these key mechanisms. It
decreases portal pressure and ameliorates hyperdynamic circu-
latory syndrome in cirrhotic rats with portal hypertension. First,
NPY markedly augments vascular contractility in cirrhotic rats
caused (among others) by enhancing Rho-kinase expression and
activity, which counteracts vascular hyporeactivity. Second,
NPY inhibits eNOS-, iNOS- and nitrergic-induced NO produc-
tion and its vasodilating effect on mesenteric arteries. Both
effects are more pronounced in cirrhotic animals as compared to
control rats. They explain the preferred effect of NPY in cirrhosis
with portal hypertension.
The SNS mediates its vasoconstrictor action predominantly
via the a1-adrenoceptor which represents the primary mecha-
nism by which it controls total peripheral resistance.29 In fact, in
the mesenteric arterial bed in humans as well as in the animal
species used in our experiments, vasoconstriction induced by
neuronally released norepinephrine is largely mediated by
activation of postsynaptic a1-adrenoreceptors.29 30 However, in
humans and animals with cirrhosis and portal hypertension
vasoconstrictors elicit less contraction in extrahepatic vessels at
least partially due to a defective Rho-kinase pathway, which is
responsible for maintaining vascular tone.10 12 NPY sensitises
the mesenteric vasculature to a1-adrenergic vasoconstriction
and markedly improves contractility in pre-hepatic portal
hypertension.19 Here, we conﬁrm these results in an experi-
mental model of liver cirrhosis known to present with a more
marked hyperdynamic circulatory syndrome and more
pronounced SNS activation than in pre-hepatic portal hyper-
tension.31 32 NPY decreases portal pressure by increases in
splanchnic vascular resistance, as well as by attenuation of
cardiac output (ﬁgures 1e3). Thus, it appears that NPY becomes
increasingly important for optimising adrenergic vasoconstric-
tion at particularly high adrenergic drive and plays a predominant
role for vascular homeostasis.
We have reported previously that patients with cirrhosis
present with elevated circulating plasma levels of NPY which
correlate with portal pressure.33 This ﬁnding indicates probably
a compensatory mechanism to counterbalance arterial vasodila-
tion through an enhanced NPY release and increased efﬁcacy
of endogenous catecholamines in the splanchnic circulation.
Beside this beneﬁcial effect, increased NPY levels might induce
angiogenesis as recently shown in heart, brain and muscle,34e36
and thus, may worsen portal hypertension due to increased portal
inﬂow. Splanchnic angiogenesis has been shown to contribute
largely to the development of the hyperdynamic circulation and
to be mainly VEGF driven.37 In this context, it is interesting to
note that NPY has been suggested to act upstream of VEGF, and
to represent a key factor for switching on the cascade of events
leading to angiogenesis.35 38 Most interestingly, NPY plasma
Figure 8 Vasomotoric protein expression and activity in superior mesenteric artery in cirrhotic rats without neuropeptide Y (NPY) (n¼5) and after i.v.
NPY administration (n¼5). Mesenteric expressions of vasoconstrictive pathway proteins RhoA, Rho-kinase and moesin were determined by western
blot analysis (A). Mesenteric expressions of vasodilating proteins eNOS, iNOS, VASP, and endogenous control GAPDH were analysed using western
blot (B). Phosphorylation of moesin, eNOS and VASP were determined by western blot analysis using phospho- and site-specific antibodies. Shown are
relative densitometric quantifications (means6SEM) of all experiments with values of controls set to 100 d.u. and representative western blots
(minimum was n¼5/group). d.u., density unit; eNOS, endothelial nitric oxide synthase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; iNOS,
inducible nitric oxide synthase; LC, liver cirrhosis; VASP, vasodilator-stimulated phosphoprotein.
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levels were found to be increased in cirrhotic patients already in
compensated Child class Awith no further increase in classes B or
C33 indicating a ceiling phenomenon of NPY release. Therefore, it
is tempting to speculate that, in the early phase of portal
hypertension increased NPY release may act as trigger for
splanchnic angiogenesis. In later stages of the disease, the ﬁndings
reported here support the hypothesis recently suggested that
there is a downregulation or at least relative insufﬁciency in SNS
activity in the splanchnic circulation.39 This insufﬁciency of SNS
and associated lack of vasoconstrictive action together with the
reported increased activity of parasympathetic system might be
partially responsible for the hyperdynamic circulation in advanced
portal hypertension.40 In vivo, exogenous NPY indeed reduced
portal tributary blood ﬂow only in cirrhotic animals and conse-
quently ameliorated portal hypertension. In addition, NPY did
not increase hepatoportal vascular resistance in cirrhotic animals
arguing against a potential opposing intrahepatic effect. More-
over, NPY had no effect on MAP pointing towards a predominant
splanchnic site of action of NPY.
We extend these in vivo observations by analysing the
mechanisms in arterial mesenteric bed in vitro. These experi-
ments show endothelium-independent beneﬁcial effects of
NPY in cirrhosis (ﬁgures 4 and 5) leading to an improvement in
vascular contractility being not observed in healthy rats. In
addition, the NPY-induced ampliﬁcation of a1-adrenergic vaso-
constriction was more pronounced in cirrhotic rats at high (but
not low) levels of a1-adrenergic prestimulation. This points
towards an improvement in the defective contractile signals of
cirrhotic vessels.10 12 Indeed, NPY increases Rho-kinase expres-
sion and activity in controls and cirrhotic rats (ﬁgures 7A, 8A).
The decrease in Rho-kinase activity in extrahepatic cirrhotic
vessels as shown earlier,10 12 was substantially restored by NPY
in cirrhotic rats. At least partially due to this effect mesenteric
contractility in vitro was improved, leading to decreased portal
inﬂow and portal pressure in vivo (ﬁgures 1A, 2A, 4B). This
effect of NPY was unknown to date, and might explain why
NPY promotes mesenteric contractility in portal hypertension.
Besides defective vasocontractile signals in extrahepatic vessels,
endothelium derived NO plays an important role for arterial
vasodialtion in cirrhosis. In addition to its effects on Rho-kinase,
NPY acts via the endothelium. It inhibited NOS induced vaso-
relaxation, and this effect was more pronounced in mesenteric
arteries of cirrhotic rats as compared to control rats (ﬁgure 6).
There are other studies on NPY, showing that it interacts with
autonomic and sensory nervous vasodilatory effects beforehand.
In detail, NPY has been shown to inhibit vasodilatory effects of
ACh (parasympathetic), substance P (sensory peptide) as well as
adenosine (sympathetic neurotransmitter) in various vascular
beds.41e45 Moreover, NPY has been shown to greatly reduce
vasorelaxation in mesenteric arteries in reponse to PNS known to
stimulate non-adrenergic and non-cholinergic (NANC) nerves.46
Interestingly, the magnitude of blockade in eNOS- and PNS-
induced vasorelaxation induced by NPY is increased in portal
hypertensive conditions. Moreover, NPYabolishes the difference in
eNOS- and nNOS-induced vasodilation between the study groups.
Since, in portal hypertension mesenteric arteries exhibit eNOS,
iNOS and nNOS upregulation4e7 22 it is tempting to speculate
that NPY may interfere with this vascular NO overproduction.
Indeed, Ishiwatari-Hayasaka et al recently reported a novel peptide
binding region for NPY close to the N-terminal domain of HSP90
a key regulator of NOS activity.47 In fact, among multiple bio-
logically active peptides screened, NPY was found to exert the
highest afﬁnity and interaction with HSP90. In line with this,
HSP90 has been shown to mediate in large parts the increased
eNOS-dependent and nitrergic vasorelaxation observed in mesen-
teric arteries in portal hypertension.49e50 Our experiments endorse
this hypothesis, since NPY administration decreased eNOS acti-
vation and NO-dependent vasodilation in mesenteric arteries,
assessed as activity of the NO effector PKG (ﬁgures 7B, 8B). It is
beyond the scope of this study to dissect the exact mechanism by
which NPY increases Rho-kinase expression and activity. One
might speculate that the potentiation of a1-adrenoceptor effect
leads to intracellular pathways that (via G-protein coupled to
RhoA) increase Rho-kinase expression and activity.
In summary, this study shows that acute intravenous admin-
istration of NPY reduces portal hypertension and ameliorates HCS
in cirrhotic rats with severe portal hypertension. This effect is
attributed to an improved arterial mesenteric contractility due to
a novel dual cellular mechanism. NPY improves Rho-kinase
activity in mesenteric arterial vascular wall and abrogates the NO
overproduction in the mesenteric vasculature making NPY a supe-
rior vasoconstrictor counterbalancing arterial vasodilatation in
portal hypertension. Therefore, NPY appears as a new therapeutic
option in humans with liver cirrhosis and portal hypertension.
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